Clozapine

Limits on what this shows

• Null/negative findings: No clinical, in vivo, human mitochondrial-function marker study (e.g., muscle biopsy respirometry, blood lactate/pyruvate ratio) in clozapine-treated patients was located.
• At-risk subgroups: Not established in humans at therapeutic dosing; theoretical, and directionally split by concentration.

Regulatory status

Not addressed in the FDA label.

Population evidence

Cells 2024 (doi 10.3390/cells13090762, human): HL60 promyeloid cells plus peripheral blood mononuclear cells and granulocytes drawn from clozapine-treated patients, at 2.5 to 20 micromolar. Oxygen consumption fell 30 to 40 percent by 48 hours; intracellular ATP dipped transiently at 8 hours then was replenished by 24 hours; glycolysis and the pentose phosphate pathway were downregulated; apoptosis was reduced, not increased, and the authors describe this as adaptive "mitohormesis" that "is an excellent way to escape energy deficits and improve cell survival." Toxicology 2023/2024 (PMID from ScienceDirect PII S0300483X23001014, rat PC12 cells): at 10 to 80 micromolar, clearly supratherapeutic against a cited therapeutic plasma range of 0.3 to 1 micromolar, clozapine caused mitochondrial membrane potential collapse and reactive-oxygen-species accumulation; overexpressing the protein PGRMC1 reversed this toxicity, while blocking it worsened injury. Toxicol In Vitro -adjacent human liposarcoma cell study (PMID 37866162): clozapine suppressed NADPH oxidase activation and counteracted cytosolic hydrogen peroxide, but triggered "early onset mitochondrial dysfunction" during adipogenesis, mechanistically tied to the drug's own weight-gain liability rather than a general depletion effect. Earlier PLOS One 2013 study (PMID 23527073): clozapine-induced mitochondrial alterations and inflammation described in brain and insulin-responsive cells.

Mechanism

Concentration-dependent: at near-therapeutic to modestly supratherapeutic exposure, clozapine appears to trigger a protective, adaptive mitochondrial stress response rather than simple depletion; only at clearly toxic, several-fold-supratherapeutic concentrations does frank mitochondrial injury appear, mediated in part through PGRMC1 signaling.

Counter-evidence held on record

The patient-cell-validated data in the Cells 2024 study explicitly argue against a simple "clozapine damages mitochondria" narrative at clinically relevant exposure, framing the effect as adaptive. This entry shares its primary human-cell source with ATP production below; see Overlap map, not two independent confirmations. Do not interpret this entry as support for mitochondrial-support supplementation such as coenzyme Q10 in patients on clozapine; no clinical trial evidence supports this, and the dominant human-relevant signal here is adaptive, not depleting.

Limits on what this shows

• Null/negative findings: No study identified measured the same oxidative marker across both a systemic (plasma) and a neutrophil-specific compartment in the same clozapine-treated patients, so the two directions described above cannot be reconciled as a single coherent pathway from the literature located.
• At-risk subgroups: Not established at the whole-body level; the neutrophil-specific pro-oxidant finding is mechanistically tied to agranulocytosis susceptibility rather than to a nutrient-deficiency-relevant subgroup.

Regulatory status

Not addressed in the FDA label.

Population evidence

Biomed Pharmacother 2018 (PMID 29710513, human, n=100 total across perphenazine, clozapine [n=36], and risperidone): clozapine recipients had significantly higher superoxide dismutase and lower lipid peroxidation than the perphenazine and risperidone groups, and glutathione correlated inversely with symptom severity, which the authors interpret as an antioxidant contribution to clozapine's clinical effect on negative symptoms. Against this, Neuropsychopharmacology /comparable journal 2005 (PMID 16160616, human, drug-specific): clozapine induced oxidative stress and proapoptotic gene expression specifically in neutrophils of schizophrenic patients, mechanistically consistent with myeloperoxidase's bioactivation of clozapine to a reactive nitrenium ion in that same cell type (a heme/iron-dependent enzymatic step implicated in agranulocytosis, MDPI Int J Mol Sci 2023 mechanistic review), which is the drug's own known toxicity pathway and is not itself graded here under Hard Rule 2. Rat brain study (PMID 17401650): chronic haloperidol and/or clozapine altered oxidative stress parameters in rat brain, direction and magnitude not fully retrieved from the abstract summary. A cardiovascular-focused human/cell study (PMID 31499544) describes clozapine disrupting endothelial nitric oxide signaling and antioxidant capacity, a vascular-tissue-specific, pro-oxidant-direction finding.

Mechanism

Tissue-specific rather than systemic: plasma/serum antioxidant enzyme activity trends favorable relative to other antipsychotics, while the neutrophil compartment specifically, where myeloperoxidase oxidizes clozapine to a reactive nitrenium ion as part of the drug's agranulocytosis mechanism, shows local pro-oxidant, proapoptotic activation. A separate study (PMID unlisted in retrieved search results, Pharmaceuticals 2025/2026, PMC12472504) reported plasma glutathione concentrations associated with leukocyte and neutrophil counts in clozapine-treated patients, but its full text could not be retrieved during this review (blocked by an automated verification page); it is listed in Sources as access-limited and not used to support this grade beyond noting its existence and topical relevance.

Counter-evidence held on record

The favorable systemic antioxidant profile and the pro-oxidant neutrophil-specific finding come from different patient cohorts and different journals and directly point in opposite directions; neither should be read as the whole picture. The neutrophil-specific mechanism is explicitly the drug's own agranulocytosis pathway (Hard Rule 2, MPO bioactivation), not evidence that clozapine causes a systemic antioxidant nutrient deficiency. This is a tissue-specific, mixed-direction context finding, not evidence that antioxidant supplementation (vitamin C, E, selenium, N-acetylcysteine) prevents or treats clozapine-induced neutropenia; no clinical trial evidence supports that use, and the mechanism involved is immune/enzymatic bioactivation, not a correctable nutrient shortfall.

Limits on what this shows

• Null/negative findings: No change in erythrocyte counts was seen in males despite the hemoglobin and RDW changes; the direction and mechanism of iron handling differed by sex (male HRI upregulation vs. female iron sequestration), so no single, unidirectional "clozapine depletes iron" claim is supported even within this one animal study.
• At-risk subgroups: Not established in humans; the animal data suggest sex may modify the pattern of iron-handling disturbance, but this has not been tested in a human clozapine cohort with direct iron-panel measurement.

Regulatory status

Not addressed in the FDA label.

Population evidence

BMC Pharmacology and Toxicology 2021 (doi 10.1186/s40360-021-00544-4, rat, drug-specific, n=10 per sex per group): clozapine approximately 18 to 20 mg/kg/day orally for roughly 12 weeks (postnatal day 85 to 165). Males: decreased hemoglobin (p=0.048), increased red-cell-distribution-width (p=0.032), markedly elevated hepatic heme-regulated inhibitor (HRI) expression (p=0.00005 vs. controls), unchanged erythrocyte counts. Females: no significant hemoglobin change, but tenfold higher hepatic ferric-iron (hemosiderin) deposition than controls (p=0.044), reflected in higher serum ferritin and liver hemosiderin. The authors interpret this as anemia secondary to clozapine-induced hepatic injury and oxidative stress, with sex-dimorphic compensatory iron-handling responses, rather than a primary dietary iron deficiency.

Mechanism

Not a classical absorption or intake-based iron-deficiency mechanism. The proposed pathway is hepatic-injury- and inflammation-driven disturbance of iron-handling proteins (ferritin, hepcidin, transferrin, HRI), consistent with the anemia-of-inflammation picture described in the human cohort under Oxygen delivery/utilization above. This is explicitly separate from the iron-heme-dependent myeloperoxidase enzyme implicated in clozapine's agranulocytosis mechanism (see Oxidative stress above); no study located tested whether a patient's iron nutritional status modifies agranulocytosis risk, and this dossier does not extrapolate that connection.

Counter-evidence held on record

This entry shares its underlying mechanistic thread (inflammation/hepcidin-mediated iron handling) with the human anemia cohort discussed under Oxygen delivery/utilization; see Overlap map. No human study directly measured ferritin or transferrin saturation in clozapine-treated patients, so this remains an animal-model, Tier B finding only. Do not supplement iron in a clozapine-treated patient based on this entry alone; if anemia is present, a lab-confirmed iron panel and inflammatory markers should guide any decision, since both iron-deficiency and iron-sequestration (functional restriction) patterns appear in the literature reviewed, and inappropriate iron supplementation in a sequestration pattern would not correct the anemia and carries its own toxicity risk (NIH Office of Dietary Supplements tolerable upper intake level for elemental iron: 45 mg/day for adults).

Limits on what this shows

• Why no grade: Both conditions for ungraded status are met: no Tier B or Tier C evidence supports even a yellow grade for clozapine specifically, and no circulating claim was located naming clozapine and copper together for this review to rebut as white.

Channels tried

PubMed search-listing pages via multiple phrasings ("clozapine copper," "clozapine copper zinc serum," "clozapine ceruloplasmin," "antipsychotic copper trace element schizophrenia treated"); direct PubMed/PMC article-page fetches (returned automated verification/redirect pages rather than content on every attempt); the Europe PMC REST API (returned a 429 rate-limit response); the Semantic Scholar Graph API (returned 429 rate-limit responses on both a direct-lookup and a search query); the NCBI eutils efetch API (blocked by the fetch tool's own robots.txt compliance check, not by NCBI itself). General schizophrenia-and-copper literature exists (a 1982 "copper hypothesis of schizophrenia" review; a dysbindin/copper-transport mechanistic paper; older studies of copper and ceruloplasmin in depot typical-neuroleptic-treated and drug-naive schizophrenia patients) but none of it stratifies to clozapine, and per Hard Rule 6 the illness-associated copper literature argues for confounding by the underlying condition rather than for a clozapine-specific drug effect, so it does not support even a class-level yellow claim here.

Outcome

No clozapine-specific copper study, in either direction, was located or could be retrieved during this review.

Genuine gap vs tooling limited

Assessed as a mix of both. It is a plausible genuine evidence gap, since even the general schizophrenia-and-copper literature is old, illness-associated rather than drug-specific, and does not single out any second-generation antipsychotic including clozapine. It is compounded by a real, disclosed tooling limitation during this specific review: the Europe PMC, Semantic Scholar, and NCBI eutils channels were each blocked or rate-limited on every attempt, preventing an exhaustive check of their full indexes. A future revision should re-attempt those three channels specifically before treating this gap as fully closed.

Limits on what this shows

• Null/negative findings: No phylum-level difference was found between the metabolic-syndrome and non-metabolic-syndrome groups; only genus-level and diversity-level differences reached significance. A separate 2026 study describing a clozapine-associated gut-lung microbiota axis linking gastrointestinal hypomotility to respiratory vulnerability was located (PMID 42129154) but its full text could not be retrieved during this review (blocked by an automated verification page on repeated attempts); it is listed in Sources as access-limited and not used to support this grade beyond noting its existence.
• At-risk subgroups: Clozapine patients who have developed metabolic syndrome; the study did not include a drug-naive or healthy-control comparison arm, so the marginal contribution of clozapine itself versus schizophrenia-associated lifestyle and diet factors cannot be isolated from this design alone.

Regulatory status

Not addressed in the FDA label; this is investigational, post-marketing observational literature.

Population evidence

Frontiers in Microbiology 2023 (PMID 37744899): cross-sectional study of 61 Han Chinese schizophrenia patients on clozapine monotherapy for at least 6 months (28 with metabolic syndrome, 33 without), using 16S rRNA sequencing. Alpha-diversity was significantly lower in the metabolic-syndrome group; beta-diversity differed significantly between groups (p<0.05). Oscillibacter abundance correlated positively with triglycerides across all groups; Gemmiger showed sex-dependent, opposite-direction correlations with lipids; in females without metabolic syndrome, Bifidobacterium, normally considered protective, showed pathogenic-direction correlations with glucose and LDL cholesterol.

Mechanism

Not established as a single causal pathway in this cross-sectional design. The authors' framing is consistent with the broader antipsychotic literature in which drug-associated weight gain and altered intestinal motility (clozapine's own well-documented gastrointestinal hypomotility, a labeled, sometimes life-threatening effect, itself excluded from grading here under Hard Rule 2) plausibly reshape the gut community, which in turn may feed back on lipid and glucose handling.

Counter-evidence held on record

No healthy-control or drug-naive comparator arm was included, so confounding by the underlying illness, diet, and institutional setting (Hard Rule 6) cannot be excluded from this study alone. The Bifidobacterium finding running in a pathogenic direction in one subgroup, rather than the uniformly protective direction usually reported for this genus, argues against a simple "clozapine depletes beneficial bacteria" narrative. No probiotic strain or dose has clinical trial support for reversing this association in clozapine-treated patients. Do not substitute probiotic supplementation for the standard metabolic monitoring (weight, glucose, lipids) already required by clozapine's own label.

Limits on what this shows

• Null/negative findings: Baseline hemoglobin and smoking were not significant protective factors in women in the human cohort, so the effect is not uniform across sexes; the rat study similarly found the mechanism (HRI upregulation vs. iron sequestration) differed by sex rather than converging on one pathway. No ferritin, transferrin saturation, or other direct iron-panel measurement was reported in the human cohort, so a classical iron-deficiency claim cannot be made from this study alone.
• At-risk subgroups: Patients in the first two years after clozapine initiation, particularly those with higher clozapine plasma exposure or elevated inflammatory markers; this is explicitly distinct from, and should not be confused with, clozapine's separate, better-known, immune-mediated white-cell toxicities (severe neutropenia, agranulocytosis), which are a different cell lineage and a different mechanism (myeloperoxidase-mediated nitrenium-ion bioactivation, discussed under Oxidative stress below) and are not filed here as an oxygen-delivery or nutrient finding.

Regulatory status

The FDA label does not list anemia or hemoglobin/hematocrit change among labeled adverse reactions or required monitoring parameters (which instead focus on absolute neutrophil count). This is a post-marketing research finding, not a labeled effect.

Population evidence

Journal of Clinical Psychiatry 2-year follow-up (PMID 26301364): 94 patients (68 men, 26 women) newly started on clozapine, complete blood counts tracked longitudinally; anemia defined as hemoglobin below 120 g/L (women) or 130 g/L (men). 23 of 94 patients (24.5 percent) developed anemia within 2 years. In men, higher baseline hemoglobin (HR 0.86, p=.002) and smoking status (HR 0.21, p=.021) were protective; neither reached significance in women. A companion letter to the same journal, citing unpublished data on the same or an overlapping cohort, reported anemic patients had higher mean clozapine plasma concentrations (771.7 plus or minus 287.1 ng/mL, n=7) than non-anemic patients (575.0 plus or minus 262.8 ng/mL, n=19), and an inverse relationship between hs-CRP and hemoglobin, consistent with anemia of inflammation.

Mechanism

Not a classical nutrient-deficiency mechanism. The hs-CRP/hemoglobin inverse relationship and the higher clozapine-exposure association in anemic patients both point toward drug-associated systemic inflammation driving hepcidin-mediated functional iron restriction (anemia of inflammation/anemia of chronic disease), rather than a dietary iron, B12, or folate deficit. A parallel Sprague-Dawley rat study (BMC Pharmacology and Toxicology 2021, doi 10.1186/s40360-021-00544-4; clozapine approximately 18 to 20 mg/kg/day orally for roughly 12 weeks, n=10 per sex per group) found decreased hemoglobin and increased red-cell-distribution-width in males (p=0.048 and p=0.032) alongside altered hepatic ferritin, transferrin-bound iron, hepcidin, and heme-regulated inhibitor (HRI) expression, with a sharply sex-dimorphic pattern: males upregulated hepatic HRI (reducing globin synthesis), while females sequestered iron as hepatic hemosiderin (tenfold higher deposition than controls, p=0.034 to 0.044). The authors framed this as hepatic-injury-mediated, not a primary dietary iron deficiency.

Counter-evidence held on record

The cohort study's own authors raised the possibility that anemia was "an epiphenomenon, characterizing instead a population with severe mental illness" rather than a direct clozapine effect; severe mental illness itself carries an elevated baseline anemia prevalence independent of any specific drug (Hard Rule 6 confounding-by-indication concern). No study identified measured ferritin, B12, or folate directly in the human cohort, so a classical nutrient-deficiency explanation cannot be confirmed or excluded from the data available. Do not attribute unexplained anemia in a clozapine-treated patient to simple dietary iron, B12, or folate deficiency, or to the drug's white-cell toxicity, without a direct iron panel, B12/folate levels, and inflammatory markers; anemia in this population may reflect an inflammatory, non-nutritional process that iron, B12, or folate supplementation would not correct, and any repletion should be prescriber-directed and lab-confirmed.

Limits on what this shows

• Null/negative findings: No in vivo or human clinical correlate (fatigue, exercise capacity, lactate) has been studied in clozapine-treated patients specifically.
• At-risk subgroups: Not established; the finding is concentration-dependent and, at the concentrations validated in patient-derived cells, trends adaptive rather than depleting.

Regulatory status

Not addressed in the FDA label.

Population evidence

Cells 2024 (doi 10.3390/cells13090762, human, HL60 cells plus patient-derived PBMCs/granulocytes, 2.5 to 20 micromolar): intracellular ATP pool decreased within the first 8 hours (not statistically significant) but was replenished by 24 hours; oxygen consumption fell 30 to 40 percent by 48 hours; glucose uptake and glycolysis were downregulated while the F0F1-ATPase inhibitory factor 1 (IF1) was upregulated to dampen, not abolish, mitochondrial respiration. The authors frame this as active metabolic reprogramming ("mitohormesis") that preserves cell survival and viability rather than an energy-production failure.

Mechanism

Proposed as an adaptive stress response (unfolded protein response and ATF4/HIF-1alpha pathway activation) that reprograms cellular energy metabolism under clozapine exposure, rather than a straightforward ATP-depletion mechanism. This entry shares its primary source with Mitochondrial burden above; see Overlap map, not counted as independent confirmation.

Counter-evidence held on record

The transient early ATP dip was not statistically significant in the source study, and the 24-hour replenishment argues against framing this as a sustained energy-production deficit at clinically relevant exposure. Does not support ATP-support supplementation, such as coenzyme Q10 or creatine, in patients on standard therapeutic clozapine dosing; no clinical trial evidence supports this use.